New Candida drug effective, with fewer ill effects

Article

-->

A new treatment for invasive candidosis and candidemia is as effective as liposomal amphotericin B but with fewer side effects, including fewer kidney function problems, researchers report online April 26 in The Lancet.

Ernst-Rudiger Kuse, MD, of the Klinik fur Viszeral und Transplantationschirurgie in Hannover, Germany, and colleagues compared results for 264 candidemia and invasive candidosis patients randomly treated with 100 mg daily of micafungin versus 267 patients given 3 mg/kg daily of liposomal amphotericin B.

After sorting cases according to neutropenia status at baseline, the researchers found a 0.7% difference in proportions. They also found that the two drugs' effectiveness did not depend on catheter status, number of blood neutrophils, main infection site, or other variables and adverse events were fewer with micafungin.

Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519-1527.

Related Videos
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Unlocking the benefits of DHEA | Image Credit: drannacabeca.com
Unlocking the power of oxytocin | Image credit: drannacabeca.com
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
Deciding the best treatment for uterine fibroids | Image Credit: jeffersonhealth.org.
Clinical pearls of pediatric dermatology | Image Credit: profiles.ucsf.edu
Approaching inflammatory vulvovaginal diseases | Image Credit: profiles.ucsf.edu.
© 2024 MJH Life Sciences

All rights reserved.